Antihypertensive therapy in obese patients with arterial hypertension
Abstract
Obesity (O) is one of the main risk factors of arterial hypertension (AH). Clinicians face increasing numbers of patients with a combination of AH and O and the problem of correct choice of antihypertensive therapy, which should effectively control blood pressure, provide cardio- and nephroprotection, and be metabolically neutral. At the present, a fixed-dose combined medication is available, which has all the characteristics required — a combination of a non-dihydropyridine calcium antagonist verapamil in its retard form and an ACE inhibitor trandolapril. This combination could be a medication of choice in patients with AH, O, diabetes mellitus and nephropathy.
About the Authors
О. M. Drapkina
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
Yu. V. Dubolazova
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. www.euro.who.int/obesity
2. Haftenberger M, Lahmann P, Panico S, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Pub Health Nutr 2002; 5: 1147-62.
3. Kim MH. Prevalence of the Metabolic Syndrome and its Association with Cardiovascular Diseases in Korea. J Korean Med Sci 2004; 19: 195-201.
4. Рекомендации по лечению артериальной гипертонии Европейского Общества Гипертонии и Европейского Общества Кардиологов 2007г.
5. Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients — focus on trandolapril/verapamil combination. Vasc Health Risk Manag 2007; 3(4): 453—65.
6. Маколкин В.И. Комбинированная терапия артериальной гипертонии: фокус на сочетание антагониста кальция и ингибитора ангиотензин-превращающего фермента. www.medi.ru
7. Bakris G, Molitch M, Hewkin A, et al.; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29(12): 2592—7.
8. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects ofsibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9(10): 1629—39.
9. Моисеев В.С., Мухин Н.А., Кобалава Ж.Д. и др. Основные положения Проекта Рекомендаций Всероссийского научного общества кардиологов и Научного общества нефрологов России по оценке функционального состояния почек у больных с сердечно-сосудистыми заболеваниями или повышенным риском их развития. Кардиоваск тер профил 2008; 7(4): 8—20.
10. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск тер профил 2004; 4 (Приложение).
11. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105—87.
12. Sandeep N, Pepine CJ, Bakris GL. Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients. Hypertension 2005; 46(4): 637—42.
13. Widimsky J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother 2000; 1(3): 515—35.
14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805—16.
15. Ruggenenti P, Fassi A, Ilieva AP, et al., for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes. NEJM 2004; 351(19):1941—51.
16. Bangalore S, Messerli FH, Cohen JD, et al.; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008; 156(2): 241—7.
17. Widimsky J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother 2000; 1(3): 515—35.
18. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9(2—3): 140—5.
19. Rubio-Guerra AF, Lozano-Nuevo JJ, Vargas-Ayala G, et al. Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens 2006; 28(7): 619—24.
Review
For citations:
Drapkina О.M., Dubolazova Yu.V. Antihypertensive therapy in obese patients with arterial hypertension. Cardiovascular Therapy and Prevention. 2009;8(4):93-97. (In Russ.)
Views:
758
Email this article 
